These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32239164)

  • 1. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
    McCarthy JS; Donini C; Chalon S; Woodford J; Marquart L; Collins KA; Rozenberg FD; Fidock DA; Cherkaoui-Rbati MH; Gobeau N; Möhrle JJ
    Clin Infect Dis; 2020 Dec; 71(10):e657-e664. PubMed ID: 32239164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel
    Sinxadi P; Donini C; Johnstone H; Langdon G; Wiesner L; Allen E; Duparc S; Chalon S; McCarthy JS; Lorch U; Chibale K; Möhrle J; Barnes KI
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
    McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
    Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
    Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
    Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimalarial efficacy of MMV390048, an inhibitor of
    Paquet T; Le Manach C; Cabrera DG; Younis Y; Henrich PP; Abraham TS; Lee MCS; Basak R; Ghidelli-Disse S; Lafuente-Monasterio MJ; Bantscheff M; Ruecker A; Blagborough AM; Zakutansky SE; Zeeman AM; White KL; Shackleford DM; Mannila J; Morizzi J; Scheurer C; Angulo-Barturen I; Martínez MS; Ferrer S; Sanz LM; Gamo FJ; Reader J; Botha M; Dechering KJ; Sauerwein RW; Tungtaeng A; Vanachayangkul P; Lim CS; Burrows J; Witty MJ; Marsh KC; Bodenreider C; Rochford R; Solapure SM; Jiménez-Díaz MB; Wittlin S; Charman SA; Donini C; Campo B; Birkholtz LM; Hanson KK; Drewes G; Kocken CHM; Delves MJ; Leroy D; Fidock DA; Waterson D; Street LJ; Chibale K
    Sci Transl Med; 2017 Apr; 9(387):. PubMed ID: 28446690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria.
    Mohammed R; Asres MS; Gudina EK; Adissu W; Johnstone H; Marrast AC; Donini C; Duparc S; Yilma D
    Am J Trop Med Hyg; 2023 Jan; 108(1):81-84. PubMed ID: 36509063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
    McCarthy JS; Lotharius J; Rückle T; Chalon S; Phillips MA; Elliott S; Sekuloski S; Griffin P; Ng CL; Fidock DA; Marquart L; Williams NS; Gobeau N; Bebrevska L; Rosario M; Marsh K; Möhrle JJ
    Lancet Infect Dis; 2017 Jun; 17(6):626-635. PubMed ID: 28363636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
    Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
    Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum.
    Barber BE; Webster R; Potter AJ; Llewellyn S; Sahai N; Leelasena I; Mathison S; Kuritz K; Flynn J; Chalon S; Marrast AC; Gobeau N; Moehrle JJ
    Int J Antimicrob Agents; 2024 Jul; 64(1):107196. PubMed ID: 38734217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
    Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the Antimalarial MMV390048 against
    Ji S; Galon EM; Rizk MA; Yi Y; Zafar I; Li H; Ma Z; Iguchi A; Asada M; Liu M; Xuan X
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0057422. PubMed ID: 35924942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
    Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
    PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
    McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
    McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.
    Chughlay MF; El Gaaloul M; Donini C; Campo B; Berghmans PJ; Lucardie A; Marx MW; Cherkaoui-Rbati MH; Langdon G; Angulo-Barturen I; Viera S; Rosanas-Urgell A; Van Geertruyden JP; Chalon S
    Am J Trop Med Hyg; 2021 Feb; 104(4):1348-1358. PubMed ID: 33556040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
    Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia.
    Yang H; Wang J; Liu H; Li X; Nie R; Li C; Wang H; Wang Q; Cao Y; Cui L
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
    McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
    Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous Expression, Purification, and Functional Analysis of the
    Sternberg AR; Roepe PD
    Biochemistry; 2020 Jul; 59(27):2494-2506. PubMed ID: 32543181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.